NASDAQ:SRRK Scholar Rock Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Scholar Rock Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. $5.33 -0.16 (-2.91%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$5.13▼$5.5650-Day Range$4.66▼$8.9152-Week Range$4.32▼$44.95Volume66,143 shsAverage Volume799,933 shsMarket Capitalization$188.16 millionP/E RatioN/ADividend YieldN/APrice Target$32.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Scholar Rock MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside512.9% Upside$32.67 Price TargetShort InterestHealthy12.23% of Float Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment0.37Based on 4 Articles This WeekInsider TradingAcquiring Shares$5.87 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.59) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.32 out of 5 starsMedical Sector185th out of 1,427 stocksBiological Products, Except Diagnostic Industry26th out of 218 stocks 3.3 Analyst's Opinion Consensus RatingScholar Rock has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.67, Scholar Rock has a forecasted upside of 512.9% from its current price of $5.33.Amount of Analyst CoverageScholar Rock has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted12.23% of the float of Scholar Rock has been sold short.Short Interest Ratio / Days to CoverScholar Rock has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scholar Rock has recently decreased by 9.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldScholar Rock does not currently pay a dividend.Dividend GrowthScholar Rock does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreScholar Rock has received a 73.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Scholar Rock is -0.74. Previous Next 3.0 News and Social Media Coverage News SentimentScholar Rock has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Scholar Rock this week, compared to 1 article on an average week.Search Interest16 people have searched for SRRK on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scholar Rock insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,870,161.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.05% of the stock of Scholar Rock is held by insiders.Percentage Held by Institutions84.22% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Scholar Rock are expected to decrease in the coming year, from ($2.59) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scholar Rock is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scholar Rock is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScholar Rock has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter. Email Address About Scholar Rock (NASDAQ:SRRK) StockScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More SRRK Stock News HeadlinesJuly 1, 2022 | finance.yahoo.comScholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)June 28, 2022 | seekingalpha.comBiopharma Scholar Rock gives up most of Monday's 23% gainJuly 4, 2022 | Investing Daily (Ad)Former Lawyer Went From $50K To $5.3M Trading OptionsSlaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M June 27, 2022 | seekingalpha.comScholar Rock rallies 27% most since 2020 after insider purchaseJune 27, 2022 | americanbankingnews.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Purchases $5,870,160.80 in StockJune 25, 2022 | americanbankingnews.comBrokers Set Expectations for Scholar Rock Holding Co.'s Q2 2022 Earnings (NASDAQ:SRRK)June 24, 2022 | finance.yahoo.comHow Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%June 24, 2022 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Given New $19.00 Price Target at Piper SandlerJuly 4, 2022 | Investing Daily (Ad)Former Lawyer Went From $50K To $5.3M Trading OptionsSlaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M June 23, 2022 | markets.businessinsider.comWhere Scholar Rock Holding Stands With AnalystsJune 22, 2022 | msn.comScholar Rock Holding Earnings Perspective: Return On Capital EmployedJune 17, 2022 | seekingalpha.comScholar Rock to raise $205M in stock and pre-funded warrant offeringJune 17, 2022 | finance.yahoo.comPositive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)June 17, 2022 | finance.yahoo.comScholar Rock Announces $205 Million Registered Direct OfferingJune 17, 2022 | finance.yahoo.comWhy Scholar Rock Shares Are Trading Higher TodayJune 14, 2022 | benzinga.comScholar Rock Holding (NASDAQ:SRRK), Short Interest ReportJune 9, 2022 | finance.yahoo.comScholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA ConferenceJune 9, 2022 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) vs. Kymera Therapeutics (NASDAQ:KYMR) Head to Head ContrastJune 8, 2022 | finance.yahoo.comWall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 413%: Read This Before Placing a BetJune 2, 2022 | finance.yahoo.comScholar Rock to Present at Jefferies Global Healthcare Conference 2022May 24, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Scholar Rock HoldingMay 20, 2022 | finance.yahoo.comDown 43.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Scholar Rock Holding Corporation (SRRK)May 17, 2022 | marketwatch.comScholar Rock Shares Rise After Restructuring >SRRKMay 17, 2022 | finance.yahoo.comScholar Rock Shares Jumps On Updating Strategic PrioritiesMay 17, 2022 | finance.yahoo.comMuscle disorder biotech to lose 39 employees, chief medical officerMay 17, 2022 | seekingalpha.comScholar Rock announces 25% workforce reductionMay 16, 2022 | finance.yahoo.comScholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic PrioritiesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRK CUSIPN/A CIK1727196 Webwww.scholarrock.com Phone(857) 259-3860Fax866-493-4935Employees145Year FoundedN/ACompany Calendar Last Earnings11/08/2021Today7/04/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$32.67 High Stock Price Forecast$55.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+512.9%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,800,000.00 Net Margins-236.95% Pretax Margin-236.95% Return on Equity-59.99% Return on Assets-37.33% Debt Debt-to-Equity Ratio0.25 Current Ratio6.85 Quick Ratio6.85 Sales & Book Value Annual Sales$18.82 million Price / Sales10.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book1.09Miscellaneous Outstanding Shares35,302,000Free Float34,578,000Market Cap$188.16 million OptionableNot Optionable Beta0.52 Scholar Rock Frequently Asked Questions Should I buy or sell Scholar Rock stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Scholar Rock stock. View analyst ratings for Scholar Rock or view top-rated stocks. What is Scholar Rock's stock price forecast for 2022? 3 Wall Street analysts have issued 1 year price targets for Scholar Rock's shares. Their SRRK stock forecasts range from $19.00 to $55.00. On average, they expect Scholar Rock's stock price to reach $32.67 in the next year. This suggests a possible upside of 512.9% from the stock's current price. View analysts' price targets for Scholar Rock or view top-rated stocks among Wall Street analysts. How has Scholar Rock's stock price performed in 2022? Scholar Rock's stock was trading at $24.84 at the beginning of the year. Since then, SRRK stock has decreased by 78.5% and is now trading at $5.33. View the best growth stocks for 2022 here. When is Scholar Rock's next earnings date? Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Scholar Rock. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Co. (NASDAQ:SRRK) issued its quarterly earnings results on Monday, November, 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.17. The business had revenue of $5.46 million for the quarter, compared to analyst estimates of $4.65 million. Scholar Rock had a negative trailing twelve-month return on equity of 59.99% and a negative net margin of 236.95%. The business's quarterly revenue was up 79.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.79) earnings per share. View Scholar Rock's earnings history. Who are Scholar Rock's key executives? Scholar Rock's management team includes the following people: Dr. Nagesh K. Mahanthappa MBA, Ph.D., Interim CEO, Pres & Director (Age 57, Pay $356.22k)Mr. Edward H. Myles M.B.A., MBA, CFO, COO & Treasurer (Age 50, Pay $615.87k) (LinkedIn Profile)Dr. Yung H. Chyung M.D., Chief Medical Officer (Age 46, Pay $613.61k)Dr. Gregory John Carven Ph.D., Chief Scientific Officer (Age 46)Ms. Catherine Hu, VP of Investor Relations & Corp. CommunicationsMs. Junlin Ho J.D., Gen. Counsel & Corp. Sec. (Age 43)Ms. Caryn Parlavecchio, Chief HR Officer (Age 50)Ms. Lisa Amaya Price, Sr. VP of HRDr. George G. Nomikos M.D., Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic AreaMs. Erin Moore, Sr. VP of Fin. (Age 47) Who are some of Scholar Rock's key competitors? Some companies that are related to Scholar Rock include iTeos Therapeutics (ITOS), Osiris Therapeutics (OSIR), Sangamo Therapeutics (SGMO), Instil Bio (TIL), NanoString Technologies (NSTG), Coherus BioSciences (CHRS), Cullinan Oncology (CGEM), Immatics (IMTX), Agenus (AGEN), Ocugen (OCGN), Century Therapeutics (IPSC), Vaxart (VXRT), Monte Rosa Therapeutics (GLUE), Immunovant (IMVT) and Inhibrx (INBX). View all of SRRK's competitors. What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA). When did Scholar Rock IPO? (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Scholar Rock's stock symbol? Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK." How do I buy shares of Scholar Rock? Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Scholar Rock's stock price today? One share of SRRK stock can currently be purchased for approximately $5.33. How much money does Scholar Rock make? Scholar Rock (NASDAQ:SRRK) has a market capitalization of $188.16 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. How many employees does Scholar Rock have? Scholar Rock employs 145 workers across the globe. How can I contact Scholar Rock? Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for Scholar Rock is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935. This page (NASDAQ:SRRK) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
